HIGHLIGHTS OF PRESCRIBING INFORMATION These ... | 合法藥品大搜索

FDA approves apalutamide for metastatic castration-sensitive prostate ... On September 17, 2019, the Food and Drug Administration approved apalutamide ... Read More

2018年5月3日 — FDA approves apalutamide for non-metastatic castration-resistant prostate cancer ... Listen to the FDA D.I.S.C.O. podcast about this approval. On ... Read More

See 17 for PATIENT COUNSELING INFORMATION and FDA- approved patient labeling. Revised: 09/2019. FULL PRESCRIBING INFORMATION: CONTENTS*. 1 INDICATIONS AND USAGE. Read More

ERLEADATM (apalutamide) tablets, for oral use. Initial U.S. Approval – 2018 ... Products, LP at 1-800-526-7736 (1-800-JANSSEN or FDA at 1-800-FDA-. Read More

2018年3月19日 — Drugs@FDA information available about ERLEADA. Persons with disabilities having problems accessing the PDF files below may call (301) ... Read More

See full prescribing information for. ERLEADA. ERLEADA® (apalutamide) tablets, for oral use. Initial U.S. Approval – 2018. --------- ... Read More

2019年9月19日 — Erleada (apalutamide) is an oral androgen receptor inhibitor for the treatment of metastatic castration-sensitive prostate cancer, and non- ... Read More

2019年10月10日 — On September 17, the U.S. Food and Drug Administration (FDA) approved apalutamide (Erleada) for patients with metastatic ... Read More

由 L Fala 著作 · 被引用 1 次 — On February 14, 2018, apalutamide (Erleada; Janssen) was approved by the US Food and Drug Administration (FDA) for the treatment of patients with ... Read More